Neuroprotective potential of saroglitazar in 6‐OHDA induced Parkinson's disease in rats
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14306 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2023. Written by Rohit Bhatt and 10 co-authors. Institution: Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, India. Major MEDLINE topics: Neuroprotective Agents, Parkinson Disease, Pyrroles. Cited 6 times so far (Crossref); 58 references.
Abstract (original language)
Parkinson's disease (PD) is a neurodegenerative disorder that affects 2%–3% of the population worldwide. Clinical presentation of PD includes motor and non‐motor symptoms. The interplay between pathogenic factors such as increased oxidative stress, neuroinflammation, mitochondrial dysfunction and apoptosis are responsible for neurodegeneration in PD. Intrastriatal administration of 6‐hydroxy dopamine (6‐OHDA) in rat brain provoked oxidative and nitrosative stress by decreasing endogenous antioxidants such as superoxide dismutase, catalase, glutathione, glutathione peroxidase and glutathione reductase. Consequently, interleukin‐6, tumour necrosis‐α, interferon‐γ and cyclooxygenase‐2 mediated neuroinflammation leads to mitochondrial dysfunction, involving inhibition of complex‐II and IV activities, followed by apoptosis and degeneration of striatal dopaminergic neurons. Degeneration of dopaminergic neurons resulted in reduced dopamine turnover, consequently induced behavioural abnormalities in rats. Activation of peroxisome proliferator‐activated receptors (PPARs) have protective role in PD by modulating response of antioxidant enzymes, neuroinflammation and apoptosis in various animal models of PD. Saroglitazar (SG) being dual PPAR‐α/γ agonist activates both PPAR‐α and PPAR‐γ receptors and provide neuroprotection by reducing oxidative stress, neuroinflammation, mitochondrial dysfunction and apoptosis of dopaminergic cells in 6‐OHDA induced PD in rats. Thereby, SG restored striatal histopathological damage and dopamine concentration in rat striatum, and behavioural alterations in rats. Thus, SG proved neuroprotective effects in rat model of PD. Potential benefits of SG in rat model of PD advocates to consider it for further preclinical and clinical evaluation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, India.
- Department of Biology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
- Department of Biotechnology, Centre for Emerging Disease, Jaypee Institute of Information Technology, Noida, India.
- Department of Biophysics, All India Institute of Medical Science (AIIMS), New Delhi, India.
- Centre of Research for Development (CR4D) and Department of Microbiology, Parul University, Vadodara, India.
- Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, India.
ORCID profiles: Saurabh Kumar Jha, Niraj Kumar Jha, Sachin Parmar
Cite
APA
Bhatt, R., Vaishnav, D., Airao, V., Sharma, T., Rachamalla, M., Mani, S., Gupta, A. K., Upadhye, V., Jha, S. K., Jha, N. K., & Parmar, S. (2023). Neuroprotective potential of saroglitazar in 6‐OHDA induced Parkinson's disease in rats. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14306
Vancouver
Bhatt R, Vaishnav D, Airao V, Sharma T, Rachamalla M, Mani S, et al. Neuroprotective potential of saroglitazar in 6‐OHDA induced Parkinson's disease in rats. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14306
BibTeX
@article{Bhatt2023,
author = {Bhatt, Rohit and Vaishnav, Devendra and Airao, Vishal and Sharma, Tejas and Rachamalla, Mahesh and Mani, Shalini and Gupta, Ashish Kumar and Upadhye, Vijay and Jha, Saurabh Kumar and Jha, Niraj Kumar and Parmar, Sachin},
title = {Neuroprotective potential of saroglitazar in 6‐OHDA induced Parkinson's disease in rats},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14306}
}
EUVIMED